I
nflammation plays a fundamental role in the development and complications of atherosclerosis (1) . One early seminal event in atherogenesis is adhesion molecule expression, a response integral to inflammatory cell entry into the vessel wall (1) . Elevated levels of triglyceride-rich lipoproteins (TRL), like very low-density lipoprotein (VLDL) and chylomicrons, induce vascular cell adhesion molecule-1 (VCAM1) expression (2) , an effect markedly augmented by inflammatory cytokines (3) . Such responses may contribute to the association between levels of TRL, the major carrier of fatty acids (FA), and atherosclerosis (4) . In contrast, VCAM1 expression is typically negligible in otherwise healthy endothelium despite exposure to TRL through both dietary sources and endogenous production (4, 5), suggesting physiologic pathways that limit adhesion molecule expression. The links between endogenous lipid metabolism and pathways that might inhibit inflammatory responses, like adhesion molecule expression, remain poorly defined.
Prior reports have demonstrated that synthetic agonists for the nuclear receptor peroxisome proliferator-activated receptor ␣ (PPAR␣) decreased VCAM1 expression induced by inflammatory stimuli, including tumor necrosis factor ␣ (TNF␣; refs. [6] [7] [8] . Consistent with these findings, certain omega 3 FA inhibited leukocyte adhesion in vivo in WT but not in PPAR␣-deficient (PPAR␣ Ϫ/Ϫ ) mice (9) . Such observations are of particular interest, given associations between increased dietary intake of omega 3 FA and reduced cardiovascular events, including atherosclerosis, as seen in recent large epidemiologic studies (10) (11) (12) .
Lipoprotein lipase (LPL) represents an appealing candidate for an enzyme whose physiologic action might limit adhesion molecule expression. LPL exerts a proximal effect in lipid metabolism, determining catabolism of nascent chylomicrons and VLDL (4) . The site of LPL action is primarily on the endothelium itself, where its activity helps determine circulating triglyceride and high-density lipoprotein (HDL) levels, known cardiovascular risk factors (13) . Both genetic and functional LPL abnormalities are directly linked to vascular pathology (14, 15) , although divergent effects have been reported, perhaps dependent on tissue-specific LPL responses (13) . Transgenic LPL overexpression decreased lesions in both apolipoprotein E (ApoE)-and low-density lipoprotein (LDL) receptor (LDLR)-deficient mouse models of atherosclerosis (14, 16) . In fact, LPL overexpression completely abrogated atherosclerosis in LDLR Ϫ/Ϫ mice despite an atherogenic diet (14) . In contrast, bone marrow transplantation of macrophages (M) overexpressing LPL into similar LDLR-deficient mice markedly increased atherosclerotic lesions (17) . Mechanisms accounting for this differential role of LPL in atherosclerosis are not clear. LPL hydrolytic function may be decreased in M (18), leaving nonenzymatic LPL-mediated lipid uptake (a result of LPL bridging lipoprotein receptors and proteoglycans) unchecked (13) .
We hypothesized that physiologic triglyceride lipolysis mediated by LPL might represent a link between lipid metabolism and PPAR activation, exerting distal PPAR effects. To examine this possibility, we studied the effects of LPL on TNF␣-induced VCAM1 responses in EC in the genetic presence or absence of PPAR␣. We further explored lipolytic activation of PPARs in vitro and in vivo, testing the role of LPL enzymatic action, different lipoprotein substrates, other FA-releasing lipases, and the PPAR isoforms involved that might form such a pathway.
Methods
Reagents and media were from Sigma or BioWhittaker, respectively, except as indicated. Fenofibric acid was a generous gift from Laboratories Fournier.
Mice with PPAR␣ ϩ/ϩ (129S3͞SvImJ) genotype were obtained from The Jackson Laboratory. PPAR␣ Ϫ/Ϫ mice were a generous gift from F. Gonzalez (National Institutes of Health; ref.
19). Mice
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overexpressing LPL in skeletal muscle (20, 21) were crossbred to homogeneity with PPAR␣ Ϫ/Ϫ mice. Cell cultures of microvascular endothelial cells (EC) were isolated from 1-mo-old PPAR␣ ϩ/ϩ and PPAR␣ Ϫ/Ϫ mouse hearts by using intercellular adhesion molecule-2 (ICAM-2) and plateletendothelial adhesion molecule-1 (PECAM-1) antibody (PharMingen) Dynabead selection (22) . HepG2 cells and HEK293 cells [American Type Culture Collection (ATCC)] were cultured in DMEM, 10% FCS. Human EC were from saphenous veins (6) . Circulating human monocytes were isolated from healthy volunteers and treated in M199 medium after differentiation (23) .
Lipoproteins were isolated by using gradient ultracentrifugation of plasma pooled from multiple healthy donors. Cholesterol, triglyceride, and protein (Pierce) contents were measured by enzymatic assay. Total free FA content was determined by enzymatic assay (Roche Molecular Biochemicals), adapted for 96-well plates (see Supporting Methods, which is published as supporting information on the PNAS web site, www.pnas.org). For labeling, VLDL was incubated (10 h, 23°C) with 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate (DiI, final concentration, 500 ng of DiI per mg of VLDL protein). Human post-heparin samples were drawn 10 min after systemic heparin infusion (60 units͞kg).
Northern analysis was done on isolated mRNA (RNEasy; Qiagen, Valencia, CA) transferred after gel electrophoresis to Hybond (Amersham Pharmacia). Immunohistochemistry was performed on frozen peripheral muscle sections by staining with rabbit PMP70 antibody (1:200; Affinity BioReagents, Neshanic Station, NJ; ref. 26 ) and secondary tetramethylrhodamine B isothiocyanate-conjugated antibody R0156 (DAKO), and analyzed by using laser-scanning confocal microscopy (MRC 600; Bio-Rad).
Scintillation proximity assays were done using human full-length cDNA for PPAR␣, PPAR␦, and hPPAR␥ 2 subcloned into the pGEX-KT expression vector as described (27) . The 3 H 2 -labeled known synthetic PPAR agonists used were compound A and compound B (see Supporting Methods) with relative K d s as follows: compound A, PPAR␥ 2.5 nM and PPAR␣ 5.0 nM; compound B, PPAR␦ 1.0 nM (27, 28) . Results are expressed as the percentage inhibition with a calculated inhibitory constant (K iS ).
VCAM1 cell surface ELISA on mouse PPAR␣ ϩ/ϩ and PPAR␣ Ϫ/Ϫ EC monolayers was performed as before (6) .
Results

LPL Opposes VLDL͞TNF␣-Induced VCAM1 Expression in a PPAR␣-
Dependent Fashion. Inflammatory cytokines induce endothelial VCAM1 expression, a response known to be augmented by either TRL or saturated FA (3, 29) . Consistent with these reports, VLDL and palmitic FA (16:0) both significantly increased VCAM1 mRNA in EC in the presence of TNF␣ (Fig. 1A , lanes 5 and 9, respectively). In contrast, LPL treatment of VLDL (LPL͞VLDL) inhibited this VCAM1 response, even in the presence of TNF␣ ( Fig.  1 A, lane 6 ). This LPL-mediated repression of induced VCAM1 equaled that seen with the synthetic PPAR␣ agonist WY14643 ( Fig.  1 A, lane 7). Neither LPL (data not shown) nor VLDL alone ( Fig.  1 A, lane 2) induced VCAM1 expression. This antiinflammatory response was also evident in VCAM1 promoter studies, with recombinant LPL (200 units͞ml) reversing TNF␣-mediated VCAM1 promoter activation in a manner dependent on VLDL substrate concentration (Fig. 1B) . Thus, LPL treatment of VLDL alters transcriptional regulation of VCAM1.
Given the possibility of PPAR-independent effects of synthetic PPAR agonists (30, 31), we next asked whether LPL͞VLDL repression of VCAM1 persisted in EC isolated from PPAR␣ Ϫ/Ϫ mice. By ELISA, PPAR␣ Ϫ/Ϫ EC had significantly higher VCAM1 levels as compared with WT EC (Fig. 2A) , consistent with the increased NF-B activation reported in PPAR␣ Ϫ/Ϫ mice (32). LPL͞VLDL limited TNF␣-induced increases in VCAM1 in WT but not in PPAR␣ Ϫ/Ϫ EC, an effect similar to that seen with a synthetic PPAR␣ agonist (Fig. 2 A) . These results suggest that LPL͞VLDL effects are mediated through PPAR␣.
LPL acts on triglycerides in lipoproteins to release FA, with relative triglyceride content of common lipoproteins following the order VLDL Ͼ Ͼ LDL Ͼ HDL. The triglyceride content (mg triglyceride per dl) in LP studied were VLDL 264 Ϯ 13.2, LDL 51 Ϯ 2.6, and HDL 24 Ϯ 1. To examine the relationship between circulating lipoproteins and LPL effects on PPAR␣, we performed standard chimeric PPAR␣-LBD͞GAL4 transfection assays (33) in primary bovine aortic EC, known to lack LPL. In the absence of added LPL, these lipoproteins failed to activate the PPAR␣-LBD (Fig. 2B) ; however, in the presence of recombinant LPL, significant PPAR␣ activation occurred in a concentration-dependent manner.
Half-maximal PPAR␣ activation values (EC 50 ) for VLDL, LDL, and HDL were 1.5, 5, and 20 g of protein per ml, respectively. Maximal induction was highest for VLDL (21-fold), followed by LDL (14-fold) and HDL (7-fold). Taken together, LPL treatment of TRL leads to significant PPAR␣ activation.
PPAR Isoform-Specific Effects of VLDL Lipolysis. Given reports that FA in vitro can activate all PPAR isoforms, we next examined these LPL͞VLDL responses in PPAR␥, PPAR␦, and PPAR␣-LBD transfection assays, and compared the responses to isoform-specific ligands (Fig. 3A) . VLDL alone had no PPAR-LBD effects. In the presence of LPL, the most potent relative induction was observed for PPAR␣, with much less of a response for PPAR␦, followed by PPAR␥ (P Ͻ 0.001). Control plasmid GAL4 remained unchanged.
As a complement to biologic LBD assays, competitive displacement of specific radioactive ligands establishes direct binding of putative ligand(s), such as LPL͞VLDL-generated products, to given expressed PPAR-LBD protein in a cell-free setting ( Fig. 3B;  ref. 27 ). These assays are independent of any noncatalytic LPL effects, like bridging (13) . Maximal radioligand displacement by LPL͞VLDL occurred against the PPAR␣-LBD (99%), with responses extending to low levels of lipoprotein substrate (K iS 0.1 g of protein per ml). Lesser effects were seen for PPAR␦ and PPAR␥, with Ϸ65% maximal displacement for both (K iS 0.3 and 1.2 g of protein per ml, respectively). LPL and VLDL added separately had no effect (data not shown). These results indicate that enzymatic hydrolysis of VLDL by LPL preferentially generates PPAR␣ ligands.
Lipase-Specific Effects of VLDL Lipolysis. To investigate PPAR activation through other lipases, LBD experiments were repeated using phospholipase A 2 , phospholipase D, phospholipase C, and LPL treatment of the major lipoprotein classes (Fig. 3C) . Despite quantitative FA release (Fig. 3D ) by all these enzymes, only LPL significantly activated PPAR␣ regardless of lipoprotein substrate. Fig. 3C is shown. The FA content in the media was measured spectrophotometrically as described in Methods, SD 5%; bars designated as in Fig. 3C . Spectrophotometric determinations correlated with palmitic acid standard in a concentration-dependent manner (data not shown).
Thus, PPAR␣ activation generated from lipoproteins depends to some extent on the lipase.
LPL͞VLDL Activation of PPAR␣ Depends on Intact LPL Enzymatic
Activity. To address how LPL͞VLDL activates PPAR␣, we asked whether PPAR␣-LBD responses depended on intact LPL enzymatic activity or, alternatively, on increased lipoprotein uptake through LPL's known bridging effect (13) . PPAR␣ϪLBD activation experiments were performed after (i) altering bridging responses by overexpressing the LDL receptor; (ii) changing proteoglycan levels with heparin and heparinase; or (iii) impairing endosomal processing with the actin inhibitor cytochalasin. None of these treatments had an effect (Fig. 4A) . The lack of PPAR␣ responses in the absence of LPL was not due to decreased lipid uptake as shown by abundant intracellular DiI-labeled VLDL even in the absence of LPL (Fig. 4B) . Thus, VLDL uptake alone is unlikely to account for PPAR␣-LBD activation. In contrast, addition of heat-inactivated LPL or transfection of a catalytically inactive LPL significantly decreased PPAR␣-LBD activation (Fig.  4A) . Furthermore, the lipase inhibitor tetrahydrolipstatin decreased LPL-mediated PPAR␣-LBD activation in a dosedependent fashion (Fig. 4C) . Thus, multiple lines of evidence indicate that generation of PPAR␣ activators from VLDL depends on intact LPL catalytic activity.
LPL͞VLDL Induces PPAR␣-Regulated Genes and Responses in a PPAR␣-
Dependent Manner in Vitro and in Vivo. To study whether LPL͞ VLDL leads to known PPAR␣ biologic responses, we examined a series of well-established PPAR␣ effects, including induction of acyl-CoA-oxidase (ACO) (34) . Transient transfection of WT LPL increases ACO expression after VLDL treatment in HepG2 cells (Fig. 5A Left) . In contrast, this response was decreased by pretreatment with the lipase inhibitor tetrahydrolipstatin or abolished by transfection of a catalytically inactive LPL. Similar effects are seen in HEK293 cells (Fig. 5A Right) . LPL treatment also induced ACO mRNA in a time-(data not shown) and VLDL concentrationdependent manner in both HepG2 (Fig. 5B ) and primary human M (Fig. 5C ). Consistent with reports of LPL itself being PPAR␣-regulated (35) , LPL͞VLDL induced LPL expression in M (Fig.  5C ), suggesting a positive feedback loop through LPL͞VLDL-activated PPAR␣.
The hallmark of PPAR␣ activation by synthetic agonists in rodents is the induction of peroxisomes. To address LPL effects in vivo in a gain of function model, peroxisome proliferation was measured by staining for the peroxisomal protein PMP70 in the skeletal muscle of LPL-overexpressing transgenic mice bred to PPAR␣ ϩ/ϩ or PPAR␣ Ϫ/Ϫ mice (Fig. 5D) . The increased PMP70-positive granules observed in LPL-overexpressing͞PPAR␣ ϩ/ϩ mice were absent in LPL-overexpressing͞PPAR␣ Ϫ/Ϫ mice. Of note, the transgenic LPL mice selected for these experiments were the ''low expression'' (MCK-L) variety, with three LPL transgene copies and an Ϸ5.5-fold increase in LPL activity (21) . Thus, increased LPL expression in vivo induces peroxisome proliferation in a PPAR␣-dependent manner. Interestingly, rodents on high-fat diets have increased peroxisomes (36) , although the mechanism for this induction has not been previously identified.
Endogenous Lipolysis in Humans Generates PPAR␣ Activators. Given this evidence for LPL-meditated PPAR␣ activation, we next asked whether similar effects could be demonstrated in humans. In plasma from six normal volunteers, minimal PPAR␣ activity was seen despite the presence of ample free FA (207 Ϯ 17 M FA; Fig.  6A ). The addition of LPL to these same samples led to a 29-fold increase in PPAR␣ LBD activity (Fig. 6A) , a response equivalent to the synthetic agonist WY14643 (20.3-fold Ϯ 0.3-fold increase). Moreover, release of endogenous tissue-bound LPL through heparin infusion led to similar PPAR␣ activation (23-fold) in the absence of adding any exogenous LPL (Fig. 6A) . These results suggest that lipolytic activity is involved in generating PPAR␣ activity of human plasma.
Discussion
Our results reveal previously uncharacterized roles for LPL, the central enzyme in triglyceride metabolism, both in limiting inflammatory responses as well as generating PPAR␣ ligands. LPL treatment of VLDL results in well-established indicators of PPAR␣ activation, including LBD responses, direct ligand displacement, induction of known PPAR␣ target genes, and peroxisome proliferation. These results were seen in vitro and in vivo in both gain of function and loss of function models. These responses suggest an endogenous metabolic pathway linking LPL enzymatic action to subsequent PPAR␣ activation and its distal transcriptional effects. To our knowledge, there exists no previously documented evidence for an enzymatic pathway leading to PPAR␣ ligand generation. Thus, LPL, an enzyme central to physiologic TRL metabolism, may replicate the effects of synthetic PPAR␣ ligands. A positive feedback loop through PPAR␣ is suggested by LPL͞VLDL-mediated induction of LPL expression itself. The functional impact of this pathway may be augmented by PPAR␣-mediated repression of the endogenous LPL inhibitor ApoCIII (37) . By examining the relationship of this lipolytic pathway to nuclear receptor activation, new insights are gained into both LPL and PPAR function.
Selectivity for the PPAR isoform targeted by LPL action is evident in vitro. PPAR␣ likely represents the major PPAR response to physiologic lipolysis, as might occur after eating. Although minimal PPAR␥ responses are seen at relevant VLDL concentrations, LPL-mediated PPAR␦ activation does occur. This PPAR␦ response through LPL may be relevant under certain circumstances and in cell types where PPAR␦ expression predominates over PPAR␣. Differences are also seen among lipases, with only certain FA-releasing enzymes generating PPAR␣-LBD activation. This specificity may derive from various lipase-specific properties: different substrates (triglyceride vs. phospholipids, saturated vs. unsaturated FA), subsequent FA modifications, and͞or the lipolytic products generated. Regardless, these results argue against the assumption based on prior in vitro data that FA in general activate PPARs (38) (39) (40) or that FA generation by any means of lipolysis would do the same. Rather, our findings suggest different transcriptional responses dependent on the specific mechanism of FA generation and uptake (Fig. 6B) .
One such example is seen in divergent FA effects on VCAM1 expression. Certain FA alone, including palmitic and stearic acids common in VLDL, augmented TNF␣-induced VCAM1 in EC. In contrast, LPL-treated VLDL, and the FA so produced, limit TNF␣-induced VCAM1 in a PPAR␣-dependent fashion, recapitulating synthetic PPAR␣ agonist effects. Thus, LPL lipolysis may represent a mechanism through which heterogeneous lipoproteins, despite containing multiple nuclear receptor ligands, including hydroxy-octadecadienoic acids (HODEs), oxidized lipids, and retinoids, can generate specific nuclear receptor responses. These results support a broader view of circulating lipoproteins as more Physiologic activation of PPAR␣ through LPL may shed new light on the widely studied but still controversial role of LPL and PPAR␣ in atherogenesis. Tordjman et al. (41) found higher triglyceride levels but unaltered fasting post-heparin LPL activity in mice lacking both PPAR␣ and ApoE, as compared with ApoE Ϫ/Ϫ alone. As those authors pointed out, their studies would not account for natural PPAR␣ ligands generated after feeding as our results would predict. Surprisingly, these ApoE Ϫ/Ϫ ͞PPAR␣ Ϫ/Ϫ mice had less atherosclerosis despite evidence that PPAR␣ activation may limit atherosclerosis and inflammation. Many factors may have contributed to the phenotype of these ApoE Ϫ/Ϫ ͞PPAR␣ Ϫ/Ϫ mice: abnormal triglyceride metabolism in ApoE Ϫ/Ϫ , known interaction between ApoE and LPL (42), improved insulin sensitivity in PPAR␣ Ϫ/Ϫ mice (41), and͞or species-specific differences in PPAR␣ responses. Recently PPAR␣ agonist treatment was reported to decrease lesional cholesterol content in ApoE Ϫ/Ϫ mice, with a more pronounced effect in ApoE Ϫ/Ϫ mice expressing a human ApoA1 transgene (43) . Cell-specific differences in PPAR␣ levels or LPL action may also influence atherosclerotic responses, for example, as seen in M (17) .
In contrast, generalized LPL overexpression dramatically decreased atherosclerotic lesions in both LDLR Ϫ/Ϫ (14) and ApoE Ϫ/Ϫ mice (16) . In humans, impaired LPL hydrolytic activity, typically associated with hypertriglyceridemia, may promote atherosclerosis, especially in diabetic patients (44) . Similarly, genetic alterations in LPL hydrolytic activity are also associated with atherosclerosis (45) . Of note, in the CARE trial, coronary heart disease risk was associated with plasma TRL levels only if combined with increased levels of the LPL inhibitor ApoCIII (46) . Our data would predict that impaired LPL enzymatic activity (for example, in diseases like diabetes) might decrease endogenous PPAR␣ activation and its subsequent downstream effects, including antiinflammatory responses. If so, fibrate therapy might be particularly important in patients with impaired LPL function, compensating for inadequate endogenous PPAR␣ ligand generation. This ''pharmacologic bypass'' of LPL-mediated PPAR␣ activation may contribute to the atherosclerotic and cardiovascular benefits seen in fibrate trials (47) .
Aside from their possible relevance to pathologic states, these findings provide a candidate physiologic mechanism uniting LPL and PPAR pathways, each of which has been previously, but separately, implicated in energy balance (13, 48) . The FA generated by LPL, as occurs postprandially, provides a major energy source through subsequent FA ␤-oxidation involving largely PPAR␣-regulated enzymes (48) . Interestingly, fasting, which results in triglyceride catabolism, induces PPAR␣ expression (49) . Thus, PPAR␣ is integral in energy supply through LPL, as after feeding or during states of increased demand, as occurs during fasting. Taken together, our findings suggest a mechanism linking physiologic metabolism of TRL and subsequent PPAR␣ transcriptional effects, implicating LPL as a key enzyme in the endogenous generation of PPAR␣ ligands.
